Fig. 2

Cell and tumor growth inhibition by T-dCyd treatment in multiple cancer cell lines and xenograft tumor models with and without deleterious TET2 and nonsynonymous DNMT3A mutations: a The cell growth inhibition by increasing concentrations, as indicated, of T-dCyd in NCI-H23 cells with TET2/DNMT3A mutations (black bars) and wildtype SKOV3 cells (gray bars), ***P < 0.0001 compared to vehicle treatment; ns, not significant (left panel). b p21 expression in NCI-H23 cells treated with T-dCyd at 48 h by Western blotting (right panel), *P < 0.05 compared to vehicle. c Cell growth inhibition by 0.5 μM of T-dCyd evaluated by clonogenic assay in mutant groups (black), wildtype group (gray) and other status (dark gray), **P = 0.007 compared between black bar group and gray/dark-gray bar groups. d Tumor growth delay [(T-C)/C] in the mutant xenograft tumors (black), and wildtype tumors (gray) by T-dCyd treatment (all dosed with 4 mg/kg of T-dCyd). Dotted line indicated 30% of tumor growth delay. C, control; ns, not significant; T, treatment